ArticleFrontiers in oncology2025
Hybrid feature fusion in cervical cancer cytology: a novel dual-module approach framework for lesion detection and classification using radiomics, deep learning, and reproducibility.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cervical cancer screening through cytology remains the gold standard for early detection, but manual analysis is time-consuming, labor-intensive, and prone to inter-observer variability. This study proposes an automated deep learning-based framework that integrates lesion detection, feature extraction, and classification to enhance the accuracy and efficiency of cytological diagnosis. Materials and methods: A dataset of 4,236 cervical cytology samples was collected from six medical centers, with lesion annotations categorized into six diagnostic classes (NILM, ASC-US, ASC-H, LSIL, HSIL, SCC). Four deep learning models, Swin Transformer, YOLOv11, Faster R-CNN, and DETR (DEtection TRansformer), were employed for lesion detection, and their performance was compared using mAP, IoU, precision, recall, and F1-score. From detected lesion regions, radiomics features (n=71) and deep learning features (n=1,792) extracted from EfficientNet were analyzed. Dimensionality reduction techniques (PCA, LASSO, ANOVA, MI, t-SNE) were applied to optimize feature selection before classification using XGBoost, Random Forest, CatBoost, TabNet, and TabTransformer. Additionally, an end-to-end classification model using EfficientNet was evaluated. The framework was validated using internal cross-validation and external testing on APCData (3,619 samples). Results: The Swin Transformer achieved the highest lesion detection accuracy (mAP: 0.94 external), outperforming YOLOv11, Faster R-CNN, and DETR. Combining radiomics and deep features with TabTransformer yielded superior classification (test accuracy: 94.6%, AUC: 95.9%, recall: 94.1%), exceeding both single-modality and end-to-end models. Ablation studies confirmed the importance of both the detection module and hybrid feature fusion. External validation demonstrated high generalizability (accuracy: 92.8%, AUC: 95.1%). Comprehensive statistical analyses, including bootstrapped confidence intervals and Delong's test, further substantiated the robustness and reliability of the proposed framework. Conclusions: The proposed AI-driven cytology analysis framework offers superior lesion detection, feature fusion-based classification, and robust generalizability, providing a scalable solution for automated cervical cancer screening. Future efforts should focus on explainable AI (XAI), real-time deployment, and larger-scale validation to facilitate clinical integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.